ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0800

Rare Overlap of Recurrent Phospholipase A2 Receptor (PLA2R)-Positive Membranous Nephropathy (MN) with Concomitant Tubulointerstitial Nephritis and Uveitis (TINU): A Case Report

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Persaud, Steven H., USF Nephrology Fellowship, Tampa, Florida, United States
  • Patel, Aditya NitinKumar, USF Observer, Tampa, Florida, United States
  • Malhotra, Ruchika, USF Nephrology Fellowship, Tampa, Florida, United States
  • Bassil, Claude, USF Nephrology Fellowship, Tampa, Florida, United States
  • P Narayanankutty, Naveen, USF Nephrology Fellowship, Tampa, Florida, United States
Introduction

TINU syndrome is a rare oculorenal syndrome that uncommonly coexists with PLA2R-positive MN. This case highlights the rare overlap of these two conditions, posing a challenge to diagnosis and treatment.

Case Description

A 23-year-old man with a history of MN diagnosed in 2020, treated with mycophenolate mofetil and prednisone, which was in remission for a few years with <1g/day of proteinuria, presented with bilateral eye redness, pain, photophobia, and headaches. Unfortunately, there was a discontinuation of medications.
Lab evaluation showed nephrotic-range proteinuria 22g/24hr, microscopic hematuria, severe hypoalbuminemia 1.2 g/dl, anemia Hgb 7.0 g/dl, elevated creatinine 6.7 mg/dl, rare eosinophiluria, thrombocytosis, positive EBV IgG and normal IgG4. The ophthalmic exam confirmed anterior uveitis. A CT guided kidney biopsy revealed PLA2R-positive MN (EM stage 3) with superimposed mild chronic active tubulointerstitial nephritis, severe interstitial fibrosis 70%, and tubular atrophy. Immunofluorescence (IF) showed subepithelial and intramembranous, electron-dense, immune complex deposits. These features suggested recurrent MN with possible TINU syndrome. Topical and systemic corticosteroids were preferred for treatment, with a plan of likely needing hemodialysis in the future due to severe interstitial fibrosis and limited use of DMARDs (disease-modifying anti-rheumatic drugs) or immunosuppressants.

Discussion

This case highlights the fact that recurrent MN can present with TINU syndrome as a clinical picture. Ophthalmologic evaluation could worthy in MN to prevent progression to TINU, if any.

Digital Object Identifier (DOI)